Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-04-23, Stock:LLY, The news for the past five days is as follows:
2019-04-15: NEWS1: J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer.NEWS2: J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer.NEWS3: J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer.
2019-04-16: NEWS1: Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales.NEWS2: Technician lays out the best bets in biotech.
2019-04-17: NEWS1: Notable Wednesday Option Activity: TNDM, VRTX, LLY.NEWS2: Notable Wednesday Option Activity: TNDM, VRTX, LLY.NEWS3: Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales.NEWS4: Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales.
2019-04-18: NEWS1: Jim Cramer: Diversification Is Good for Offense, Not Just Defense.NEWS2: Pfizer, Lilly shares decline as osteoarthritis drug misses goals in study.NEWS3: Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study.NEWS4: Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline.NEWS5: Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline.NEWS6: Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline.
2019-04-22: NEWS1: The best companies for employees in 2019.NEWS2: Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study.NEWS3: Update: Eli Lilly (NYSE:LLY) Stock Gained 97% In The Last Five Years.NEWS4: Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns.NEWS5: Health Care Sector Update for 04/22/2019: ISRG, AXGN, LLY, JNJ, PFE, ABT, MRK, AMGN.NEWS6: Health Care Sector Update for 04/22/2019: ISRG, AXGN, LLY, JNJ, PFE, ABT, MRK, AMGN.NEWS7: Eli Lilly stock down 3.4% despite positive Phase 3 findings for Taltz.NEWS8: Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis.NEWS9: Lilly and Avidity Biosciences Announce Licensing and Research Collaboration.

Answer: Rise